These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 16421019)

  • 21. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
    Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
    J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes.
    Miki S; Ksander B; Streilein JW
    Reg Immunol; 1992; 4(6):352-62. PubMed ID: 1297406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphoma allografts abrogate immune privilege within the anterior chamber of the eye.
    Niederkorn JY; Streilein JW
    Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1235-43. PubMed ID: 3089965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters.
    Zatloukal K; Schneeberger A; Berger M; Schmidt W; Koszik F; Kutil R; Cotten M; Wagner E; Buschle M; Maass G
    J Immunol; 1995 Apr; 154(7):3406-19. PubMed ID: 7897222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Termination of immune privilege in the anterior chamber of the eye when tumor-infiltrating lymphocytes acquire cytolytic function.
    Ksander BR; Mammolenti MM; Streilein JW
    Transplantation; 1991 Jul; 52(1):128-33. PubMed ID: 1907041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adoptive transfer of immunity to intraocular tumors in mice.
    Niederkorn JY; Streilein JW
    Invest Ophthalmol Vis Sci; 1984 Mar; 25(3):336-42. PubMed ID: 6421767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
    Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
    Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promotion of syngeneic intraocular tumor growth in mice by anterior chamber-associated immune deviation.
    Niederkorn JY; Streilein JW; Kripke ML
    J Natl Cancer Inst; 1983 Jul; 71(1):193-9. PubMed ID: 6575203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracamerally induced concomitant immunity: mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge.
    Niederkorn JY; Streilein JW
    J Immunol; 1983 Nov; 131(5):2587-94. PubMed ID: 6415174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
    Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
    Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
    Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
    Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine.
    Marshall DJ; Rudnick KA; McCarthy SG; Mateo LR; Harris MC; McCauley C; Snyder LA
    Vaccine; 2006 Jan; 24(3):244-53. PubMed ID: 16135392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of anterior chamber-associated immune deviation (ACAID) by allogeneic intraocular tumors does not require splenic metastases.
    Niederkorn JY; Streilein JW
    J Immunol; 1982 Jun; 128(6):2470-4. PubMed ID: 6804562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination.
    Liau LM; Jensen ER; Kremen TJ; Odesa SK; Sykes SN; Soung MC; Miller JF; Bronstein JM
    Cancer Res; 2002 Apr; 62(8):2287-93. PubMed ID: 11956085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism.
    Dace DS; Chen PW; Niederkorn JY
    J Immunol; 2007 May; 178(10):6115-22. PubMed ID: 17475837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-1 abrogates anterior chamber-associated immune deviation.
    Benson JL; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1990 Oct; 31(10):2123-8. PubMed ID: 1698740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impaired induction of delayed hypersensitivity following anterior chamber inoculation of alloantigens.
    Williamson JS; Streilein JW
    Reg Immunol; 1988; 1(1):15-23. PubMed ID: 2978942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-1 receptor antagonist suppresses Langerhans cell activity and promotes ocular immune privilege.
    Dana MR; Dai R; Zhu S; Yamada J; Streilein JW
    Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):70-7. PubMed ID: 9430547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.